Lucia Mentuccia
Colleferro, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Journal: Therapeutic advances in medical oncology
Published: May 18, 2021
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Journal: Journal of cellular physiology
Published: November 08, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Journal: International journal of cancer
Published: April 15, 2019
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Journal: Journal of geriatric oncology
Published: February 21, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: January 08, 2019
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Journal: Cancer biology & therapy
Published: November 08, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: October 24, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Journal: Journal of cellular physiology
Published: October 10, 2018
The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy.
Journal: Current problems in cancer
Published: October 10, 2018
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Journal: Breast care (Basel, Switzerland)
Published: July 23, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: April 02, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Journal: Cancer biology & therapy
Published: January 17, 2018
Last Updated: 09/26/2026